Summary & Overview
HCPCS J7328: Hyaluronan (gelsyn-3) Intra‑articular Injection, 0.1 mg
HCPCS Level II code J7328 covers hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg, a viscosupplementation product used in joint management. Nationally, this code identifies a specific injectable biologic administered directly into joint spaces, relevant for orthopedic, rheumatology, and pain-management billing. Accurate coding affects clinical documentation, claims processing, and appropriate benefit determination for patients receiving intra-articular hyaluronan therapies.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, reimbursement benchmarks, permitted settings of care, and typical claim administration for intra-articular hyaluronan products using this HCPCS Level II identifier.
Readers will learn what J7328 represents clinically, where the service is typically delivered, and how payers commonly approach coverage and payment for hyaluronan injections. The piece also reviews relevant billing considerations such as unit reporting, common modifiers, and how this code fits into broader clinical workflows. Policy updates and national reimbursement context are summarized to provide actionable intelligence for revenue cycle, clinical coding, and compliance teams.
Billing Code Overview
HCPCS Level II code J7328 represents hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg. This code denotes a prescription biologic formulation intended for intra-articular administration, used in joint spaces to provide viscosupplementation.
Service Type: Intra-articular injection of hyaluronan derivative
Typical Site of Service: Outpatient clinic, physician office, or ambulatory surgical center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with symptomatic osteoarthritis of the knee presents to an outpatient orthopedic clinic with persistent medial joint line pain, intermittent swelling, and reduced range of motion despite conservative care (activity modification, oral analgesics, physical therapy, and a prior course of intra-articular corticosteroid). The clinician documents focal degenerative cartilage loss on examination and confirms radiographic evidence of osteoarthritis. After shared decision-making, the clinician administers an intra-articular viscosupplementation injection using J7328 (hyaluronan derivative, gelsyn-3, 0.1 mg) into the affected knee under aseptic technique.
Workflow:
-
The patient registers at the outpatient clinic and completes consent and medication/allergy reconciliation.
-
The clinician reviews recent imaging, documents the indication (knee osteoarthritis), and verifies no contraindications (active infection, allergy to hyaluronan product).
-
The procedure is performed in an exam room or ambulatory procedure area: skin antisepsis, optional local anesthetic, joint localization, and ultrasound guidance if needed.
-
The product
J7328is prepared and drawn per manufacturer instructions; any discarded portion is documented if applicable. -
The injection is administered intra-articularly; post-procedure observation is brief and discharge instructions provided regarding activity and expected post-injection soreness.
-
Documentation includes product name and HCPCS
J7328, lot number, units dispensed, site of service, indication (e.g., osteoarthritis of knee), informed consent, and any immediate complications.